Back

Dutch HIPEC

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Date of Publication:

December 18, 2018

Pubmed Link:
https://www.ncbi.nlm.nih.gov/pubmed/29342393
Hypothesis:

Does addition of heated IP chemo at the time of interval cytoreduction improve survival in advanced ovarian cancer?

Control Arm(s):

Interval cytoreduction

3 cycles of Carboplatin (AUC 5/6) + Paclitaxel (175 mg/m2)

Experimental Arm(s):

Interval cytoreduction + HIPEC (100 mg/m2 cisplatin x 90 minutes at 40°C)

3 cycles of Carboplatin (AUC 5/6) + Paclitaxel (175 mg/m2)

Primary End Point:

PFS

Inclusion Criteria:

Stage III ovarian cancer

3 cycles of neoadjuvant carbo/taxol with at least partial response

Residual disease ≤1cm

Exclusion Criteria:
Results:

Surgery + HIPEC (n=122) vs. Surgery (n=123)

median f/u: 4.7 yrs

Median PFS: 14.2 vs 10.7 mos (SS)

median OS: 45.7  vs 33.9 mos (SS)

Median duration of surgery: 338 vs 192 minutes

Median hospital LOS: 10 vs 8 days (1 day in ICU specified by protocol)

Toxicities were balanced between groups

No differences in timing of chemo restart or rates of post-surgery chemo completion

Conclusions:

Addition of HIPEC to complete or optimal interval cytoreductive surgery resulted in longer PFS and OS than surgery alone in women with advanced ovarian cancer

Reviewer:
Kevin McCool, OTF